{
    "clinical_study": {
        "@rank": "80463", 
        "arm_group": {
            "arm_group_label": "GS-9820", 
            "arm_group_type": "Experimental", 
            "description": "Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy."
        }, 
        "brief_summary": {
            "textblock": "This study is to determine the appropriate dosing regimen of GS-9820 in subjects with\n      lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study\n      evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of\n      GS-9820."
        }, 
        "brief_title": "A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoid Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously treated recurrent B-cell iNHL, DLBCL, MCL, HL or CLL\n\n          -  Measurable lymphadenopathy\n\n          -  Requires therapy\n\n        Exclusion Criteria:\n\n          -  Recent history of a major non-lymphoid malignancy\n\n          -  Evidence of ongoing infection\n\n          -  Concurrent participation in another therapeutic clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705847", 
            "org_study_id": "GS-US-315-0102", 
            "secondary_id": "2012-000360-19"
        }, 
        "intervention": {
            "arm_group_label": "GS-9820", 
            "description": "GS-9820 tablets containing 200 mg of GS-9820 administered orally", 
            "intervention_name": "GS-9820", 
            "intervention_type": "Drug", 
            "other_name": "CAL-120"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic lymphocytic leukemia (CLL)", 
            "non-Hodgkin lymphoma (NHL)", 
            "Hodgkin lymphoma (HL)", 
            "indolent non-Hodgkin lymphoma (iNHL)", 
            "diffuse large B-cell lymphoma-activated B-cell (DLBCL-ABC)", 
            "DLBCL-germinal center B-cell (GCB)", 
            "mantle cell lymphoma (MCL)", 
            "GS-9820", 
            "phosphatidylinositol 3-kinase (PI3K)"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academic Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081 HV"
                    }, 
                    "name": "VU Medical Center (VUmc)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "zip": "3435 CM"
                    }, 
                    "name": "St. Antonius Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Erasmus MC - Daniel den Hoed Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies", 
        "overall_official": {
            "affiliation": "Academic Medical Center, University of Amsterdam", 
            "last_name": "Arnon P Kater, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MTD will be assessed to determine the appropriate dosing regimens for use in future clinical trials of GS-9820 in subjects with lymphoid malignancies.", 
            "measure": "Maximum tolerated dose (MTD)", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705847"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall safety will be assessed by overall safety profile, enumeration and description of any dose-limiting toxicities, serious adverse events, or adverse events leading to discontinuation of study drug.", 
                "measure": "Overall safety", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Cmax is defined as the maximum concentration of drug\nTmax is defined as the time of Cmax\nCtrough is defined as the trough concentration\nAUC is defined as the area under the plasma concentration versus time curve", 
                "measure": "Pharmacokinetic parameters of GS-9820 as measured by Cmax, Tmax, Ctrough, and AUC", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 29"
            }, 
            {
                "measure": "Pharmacodynamics to measure changes in the phosphatidylinositol 3-kinase  (P13K) delta pathway activation and changes in plasma concentration of disease-associated chemokines and cytokines", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 29"
            }, 
            {
                "description": "Tumor control as assessed by overall response rate (ORR), time to response (TTR), duration of response (DOR), progression-free survival (PFS), percent change in lymph node area, lymph node response rate, splenomegaly response rate, ALC response rate, hepatomegaly response rate, platelet response rate, hemoglobin response rate, and neutrophil response rate.", 
                "measure": "Tumor control", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Patient well-being assessed using changes in baseline in HRQL (health related quality of life questionnaire) domain and symptom scores based on the Functional Assessment of Cancer Therapy: Lymphoma (FACT-Lym)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Drug administration for GS-9820 as assessed by prescribing records and GS-9820 compliance as assessed by quantification of used and unused drug.", 
                "measure": "Drug exposure", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}